Identification and Validation of lncRNA-AC087588.2 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic Indicator

Frontiers in Molecular Biosciences

卷:9

Xi Chen¹  Jun Pu¹  Xiaoqun Niu²  Fan Zhou³  Jishu Guo⁴  Xiulin Jiang⁵  Luciano Mutti⁶ 

[1] Department of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China;

[2] Department of Respiratory Medicine, Second Hospital of Kunming Medical University, Kunming, China;

[3] Hematology and Rheumatology Department, The Pu’er People’s Hospital, Puer, China;

[4] Institute for Ecological Research and Pollution Control of Plateau Lakes, School of Ecology and Environmental Science, Yunnan University, Kunming, China;

[5] Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing, China;

[6] Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United States;

关键词: lncRNA;    lung adenocarcinoma;    prognosis biomarker;    immune infiltration;    ceRNA;    cell proliferation;   

DOI  :  10.3389/fmolb.2022.923584

来源: DOAJ

【 摘 要 】

Lung adenocarcinoma (LUAD) is the most common histological lung cancer, and it is the leading cause of cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) have been implicated in the initiation and progression of various cancers. LncRNA-AC087588.2 (ENSG00000274976) is a novel lncRNA that is abnormally expressed in diverse cancer types, including LUAD. However, the clinical significance, prognostic value, diagnostic value, immune role, and the potential biological function of AC087588.2 LUAD remain elusive. In this study, we found that AC087588.2 was upregulated and associated with a poor prognosis in LUAD. In addition, univariate and multivariate Cox regression analysis indicated that AC087588.2 could be an independent prognostic factor for LUAD. Functionally, the knockdown of AC087588.2 restrained LUAD cell proliferation and migration in vitro. Finally, we constructed a ceRNA network that included hsa-miR-30a-5p and four mRNAs (ANLN, POLR3G, EHBP1, and ERO1A) specific to AC087588.2 in LUAD. The Kaplan–Meier survival analysis showed that lower expression of hsa-miR-30a-5p and higher expression of ANLN, POLR3G, EHBP1, and ERO1A were associated with adverse clinical outcomes in patients with LUAD. This finding provided a comprehensive view of the AC087588.2-mediated ceRNA network in LUAD, thereby highlighting its potential role in the diagnosis and prognosis of LUAD.

【 授权许可】

Unknown